

Justice Oehlert, PharmD, Kyle Hommer, PharmD, Kat Lincoln, PharmD, BCPS, BCIDP

Background

- Methicillin-resistant *Staphylococcus aureus* (MRSA) is a drug resistant pathogen commonly covered empirically in patients with hospital acquired pneumonia (HAP), ventilator acquired pneumonia (VAP) and community acquired pneumonia (CAP) if multi-drug resistant organism risk factors are present per recommendations from the Infectious Diseases Society of America (IDSA).¹⁻²
- Clinicians are often reluctant to de-escalate therapy if respiratory cultures have not finalized, which may lead to extended, often unnecessary exposure to antibiotics.
- The decision to de-escalate therapy can be guided by a negative MRSA colonization screening.¹⁻²
- The negative predictive value (NPV) of MRSA screenings was reported as 96.5% in the largest meta-analysis to date.³

Purpose

- Compare days of therapy (DOT) of MRSA-targeted antibiotics before and after the implementation of a protocol allowing pharmacists to order MRSA nasal screenings in patients with pneumonia.

Study Endpoints

Primary endpoint

- Median days of therapy (DOT)

Secondary endpoints

- Length of stay (LOS)
- Pharmacists' adherence to protocol
- Number of vancomycin and linezolid doses administered
- Number of vancomycin trough levels obtained

Methods

- Chart review of patients receiving vancomycin or linezolid for pneumonia during admission at OMC pre- and post-guideline implementation, July 2020 to October 2020 and December 2020 to March 2021, respectively.
- Patients were excluded if they had a positive MRSA screening, MRSA respiratory isolate, presence of another infection requiring MRSA coverage, were less than 18 years old, pregnant, or incarcerated.
- MRSA screenings were performed using swabs obtained from a patient's nares and plated on MRSA growth media.
- Nominal data were analyzed using the χ^2 test.
- Continuous data were analyzed using the t-test or Mann-Whitney *U* test.

Figure 1 – MRSA Screening Protocol

A pharmacist may order MRSA nasal screening if the following criteria are met:

- Diagnosis of pneumonia or "sepsis, source unknown"
- Vancomycin or linezolid ordered
- Exclusions
 - Confirmed MRSA in respiratory cultures from present admission
 - MRSA nares previously ordered during admission
 - Bronchoalveolar lavage pending

Results

A total of 219 patients were included, 136 and 83 in the pre- and post-intervention groups, respectively. 277 charts were reviewed, and 58 patients were excluded due to positive MRSA screenings, isolation of MRSA in respiratory cultures, or concurrent infections requiring MRSA-targeted therapy.


Population Characteristics (n=219)

Table 1 – Selected Baseline Patient Characteristics

	Pre-protocol mean or %	Post-protocol mean or %	p-value
Average age, years	69.7	71.5	0.35
Sex, male	59.6	65.1	0.42
Serum creatinine, mg/dL	1.7	1.8	0.52
Tmax, °C	37.8	37.9	0.46
Procalcitonin, ng/ml	2.1	1.4	0.37
Lactate, mmol/L	2.5	2.6	0.94
ICU admission	37.5	44.6	0.30
CAP	46.3	31.1	0.03
HCAP	42.6	48.2	0.42
HAP	8.8	16.9	0.07
VAP	2.2	3.6	0.54
CURB-65 score	2.0	2.4	0.03

Tmax: maximum temperature, ICU: Intensive care unit, HCAP: healthcare-associated pneumonia, CURB-65: confusion, uremia, respiratory rate, blood pressure, age>65

Figure 2 – Selected Statistically Significant Between Group Differences



WOC: withdrawal of care, BMI: body mass index

Figure 3 – MRSA Screening Rates (p<0.00001)




Figure 4 – Primary and Secondary Endpoints




Table 2 – Exploratory Outcomes

	Pre-protocol (COVID excluded)	Post-protocol (COVID excluded)	p-value
DOT- median, [IQR]	3, [1.8-4]	2, [1-3]	0.32
	Pre-protocol	Post-protocol (nares ordered)	p-value
DOT- median, [IQR]	3, [1-4]	2, [1-3.3]	0.34

Conclusions

- The implementation of a pharmacist-driven MRSA screening protocol increased screening rates but did not significantly decrease average duration of MRSA targeted therapy in patients with pneumonia.
- Subgroup analyses that attempted to control for between group differences yielded similar results.
- Polymerase chain reaction (PCR) assays, as opposed to traditional plate cultures utilized in this study, will be needed to further evaluate the effectiveness of this protocol.

Limitations

- Due to the presence of significant confounders, namely differences in COVID infection rates and death/WOC rates, interpretation of these results are limited.
- Pre-and post-intervention groups were not matched for calendar months due to the COVID-19 pandemic to ensure COVID was present for both groups; furthermore, the unpredictability of the pandemic made it impossible to foresee future infection rates.
- Effectiveness of the protocol is limited by the unavailability of PCR based screening methods.

References

- Metlay J, Waterer G, Long A, et al. *AM J Respir Crit Care Med.* 2019;200(7):e45-e67.
- Kalil A, Metersky M, Klompas M, et al. *Clin Infect Dis.* 2016;63(5):e61-e111.
- Parente DM, Cunha CB, Mylonakis E, et al. *Clin Infect Dis.* 2018; 67(1): 1-7. doi: 10.1093/cid/ciy024.